DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 73.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,767 shares of the medical device company’s stock after selling 16,074 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in DexCom were worth $800,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. DSM Capital Partners LLC bought a new position in DexCom during the fourth quarter valued at about $28,000. Valley National Advisers Inc. boosted its position in shares of DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Riverview Trust Co acquired a new position in shares of DexCom in the 1st quarter worth approximately $32,000. MV Capital Management Inc. raised its holdings in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares in the last quarter. Finally, Smithfield Trust Co lifted its position in shares of DexCom by 103.1% during the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after acquiring an additional 165 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Citigroup raised their target price on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. UBS Group upped their target price on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Raymond James lifted their target price on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Robert W. Baird cut DexCom from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $161.00 to $80.00 in a research note on Friday. Finally, Stifel Nicolaus decreased their price objective on shares of DexCom from $145.00 to $132.00 and set a “buy” rating for the company in a report on Friday, July 12th. Six research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $134.33.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 629 shares of the stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total value of $79,411.25. Following the completion of the transaction, the executive vice president now directly owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Sadie Stern sold 427 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now owns 75,877 shares in the company, valued at $8,729,648.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Jon Brown sold 629 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total transaction of $79,411.25. Following the completion of the sale, the executive vice president now owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The disclosure for this sale can be found here. Insiders sold a total of 4,112 shares of company stock worth $480,861 over the last quarter. Company insiders own 0.30% of the company’s stock.

DexCom Stock Down 3.7 %

NASDAQ DXCM opened at $107.85 on Friday. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The stock has a market cap of $42.89 billion, a PE ratio of 69.58, a PEG ratio of 2.74 and a beta of 1.16. The firm has a 50-day simple moving average of $116.63 and a 200 day simple moving average of $124.29.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.04. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.34 EPS. On average, research analysts forecast that DexCom, Inc. will post 1.78 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.